Licence Changes & Product Updates

MST Continus granules to be discontinued

MST Continus granules to be discontinued

1 March 2021, 10:43am

All strengths of MST Continus (morphine) prolonged-release...

Phyllocontin to be discontinued

Phyllocontin to be discontinued

15 February 2021, 4:43pm

Phyllocontin Continus 225mg and Phyllocontin Forte...

Majority of COVID-19 vaccine side-effects 'mild and short lasting', MHRA analysis confirms

Majority of COVID-19 vaccine side-effects 'mild and short lasting', MHRA analysis confirms

5 February 2021, 11:13am

Most adverse reactions reported for the Pfizer/BioNTech...

First triple combination MDI licensed for asthma

First triple combination MDI licensed for asthma

21 January 2021, 12:30pm

Trimbow (beclometasone/formoterol/glycopyrronium) can...

Levosert IUS approved for extended contraceptive use

Levosert IUS approved for extended contraceptive use

19 January 2021, 3:16pm

Levosert (levonorgestrel) IUS can now be used to provide...

FemSeven Conti back in stock

FemSeven Conti back in stock

18 January 2021, 11:11am

FemSeven Conti (estradiol/levonorgestrel) HRT patches...

Elleste HRT range back in stock

Elleste HRT range back in stock

21 December 2020, 10:36am

The full range of Elleste HRT products is now back...

NICE recommends further migraine prevention option

NICE recommends further migraine prevention option

23 November 2020, 5:43pm

Galcanezumab (Emgality) is the second calcitonin gene-related...

Diabetes drug approved to treat heart failure

Diabetes drug approved to treat heart failure

11 November 2020, 10:57am

Forxiga (dapagliflozin) is the first SGLT2 inhibitor...

New tablet treatment for eczema

New tablet treatment for eczema

28 October 2020, 5:13pm

Prescribers have a new oral treatment option for patients...

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.